ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.
馬薩諸塞州劍橋和安大略省多倫多，2024年8月1日（GLOBE NEWSWIRE）——專注於開發針對神經退行性疾病中毒性錯誤摺疊蛋白的療法的生物技術公司ProMis Neurosciences Inc.（納斯達克股票代碼：PMN）今天宣佈，ProMis神經科學臨時首席執行官尼爾·瓦爾瑪和ProMis神經科學首席醫學官拉里·阿爾茨蒂爾萬博士博士，將於美國東部時間2024年8月6日中午12點參加BTIG虛擬生物技術會議的爐邊談話
A live webcast of the fireside chat will be available to conference participants.
會議參與者將觀看爐邊聊天的網絡直播。
About ProMIS Neurosciences Inc.
關於 PromiS Neuroscienc
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.
ProMis Neurosciences Inc. 是一家臨床階段的生物技術公司，專注於研發選擇性地針對阿爾茨海默氏病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA）等神經退行性疾病中毒性錯誤摺疊蛋白質的抗體療法。該公司專有的靶標發現引擎應用熱力學計算發現平台——ProMIS和集體座標——來預測錯誤摺疊蛋白分子表面上被稱爲疾病特異表位的新靶標。使用這種獨特的方法，該公司正在開發針對AD、ALS和MSA的新型抗體療法。ProMis在安大略省多倫多和馬薩諸塞州劍橋設有辦事處。
For further information:
欲了解更多信息：
Visit us at
請訪問我們
Please submit media inquiries to info@promisneurosciences.com.
請將媒體查詢提交至 info@promisneurosciences.com。
For Investor Relations, please contact:
Precision AQ
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
有關投資者關係，請聯繫：
精度 AQ
安妮·瑪麗·菲爾茲，董事總經理
annemarie.fields@precisionaq.com
電話 212-362-1200